BioNTech SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNTX research report →
About the company
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
- CEO
- Ugur Sahin
- IPO
- 2019
- Employees
- 6,772
- HQ
- Mainz, DE
Price Chart
- Market Cap
- $24.67B
- P/E
- -16.71
- P/S
- 7.63
- P/B
- 1.14
- EV/EBITDA
- -16.68
- Div Yield
- 0.00%
- Gross Margin
- 77.60%
- Op Margin
- -52.06%
- Net Margin
- -44.67%
- ROE
- -6.67%
- ROIC
- -7.52%
- Revenue
- $2.76B · 0.20%
- Net Income
- $-1,091,261,192 · -64.03%
- EPS
- $-4.51 · -62.82%
- Op Income
- $-623,865,983
- FCF YoY
- 210.31%
- 52W High
- $124.00
- 52W Low
- $79.52
- 50D MA
- $93.37
- 200D MA
- $99.11
- Beta
- 1.32
- Avg Volume
- 960.55K
Get TickerSpark's AI analysis on BNTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Low-Friedrich Iris Katharina | other | 0 |
| Jun 26, 26 | Schaffert Susanne | other | 0 |
| May 12, 26 | Zapata Gomez Ramon | other | 18,879 |
| May 12, 26 | Zapata Gomez Ramon | other | 15,103 |
| May 12, 26 | Ryan James Timothy Patrick | other | 12,586 |
| May 12, 26 | Ryan James Timothy Patrick | other | 10,069 |
| May 12, 26 | Poetting Sierk | other | 12,586 |
| May 12, 26 | Poetting Sierk | other | 10,069 |
| May 12, 26 | Jimenez Kylie | other | 10,488 |
| May 12, 26 | Jimenez Kylie | other | 8,391 |
Our BNTX coverage
Recent articles, reports, and earnings notes.
No research on BNTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNTX report →Similar companies
Peers in the same neighborhood.